High-dosage buprenorphine (BUP) consumed concomitantly with benzodiazepines (BZDs) including flunitrazepam (FZ) may cause life-threatening respiratory depression despite a BUP ceiling effect and BZDs' limited effects on ventilation. However, the mechanism of BUP/FZ interaction remains unknown. We hypothesized that BUP may alter the disposition of FZ active metabolites in vivo, contributing to respiratory toxicity. Plasma FZ, desmethylflunitrazepam (DMFZ), and 7-aminoflunitrazepam (7-AFZ) concentrations were measured using gas chromatography-mass spectrometry. Intravenous BUP 30 mg/kg pretreatment did not alter plasma FZ and 7-AFZ kinetics in Sprague-Dawley rats infused with 40 mg/kg FZ over 30 min, whereas resulting in a three-fold increase in the area under the curve (AUC) of DMFZ concentrations compared with control (p < 0.01). In contrast, BUP did not significantly modify plasma DMFZ concentrations after intravenous infusion of 7 mg/kg DMFZ, whereas resulting in a similar peak concentration to that generated from 40 mg/kg FZ administration. Regarding the effects on ventilation, BUP (30 mg/kg) as well as its combination with FZ (0.3 mg/kg) significantly increased PaCO(2), whereas only BUP/FZ combination decreased PaO(2) (p < 0.001). Interestingly, FZ (40 mg/kg) but not DMFZ (40 mg/kg) significantly increased PaCO(2) (p < 0.05), whereas DMFZ but not FZ decreased PaO(2) (p < 0.05). Thus, decrease in PaO(2) appears related to BUP-mediated effects on DMFZ disposition, although increases in PaCO(2) relate to direct BUP/FZ additive or synergistic dynamic interactions. We conclude that combined high-dosage BUP and FZ is responsible for increased respiratory toxicity in which BUP-mediated alteration in DMFZ disposition may play a significant role.
Obstructive Sleep Apnea (OSA) is a prevalent condition thought to increase in the future.
Being mostly undiagnosed, the most serious complications are cardiovascular diseases, among
which are arrhythmias. Controversy remains as to whether OSA is a primary etiologic factor for
ventricular arrhythmias, because of the high incidence of cardiovascular comorbidities in OSA patients.
However, there is mostly a strong evidence of a relation between OSA and ventricular arrhythmias.
A few mechanisms have been proposed to be responsible for this association and some
electrocardiographic changes have also been demonstrated to be more frequent in OSA patients.
Treatment of OSA with Continuous Positive Airway Pressure (CPAP) has the potential to reduce
arrhythmias and confer a mortality benefit.
BackgroundIron metabolism disorders have been associated with an increased risk of
cardiovascular events. However, the prognostic impact on patients (pts) with
acute coronary syndrome (ACS) has yet to be clarified.ObjectiveTo determine the prognostic value of serum iron and ferritin levels in pts
with ACS in the short and long-term.MethodsConsecutive pts admitted to a coronary care unit with a diagnosis of ACS, for
a period of 2 years, were evaluated. The population was divided into
tertiles of serum iron and ferritin distribution. The primary adverse events
were the occurrence of in-hospital death or heart failure (HF) and death or
HF at 1 year of follow-up.ResultsWe studied 280 pts (73% males; mean age 68 ± 13 years). The mean
levels of serum iron and ferritin were 59 ± 34 mcg/dL and 205
± 185 ng/mL, respectively. Patients included in the 1st
tertile of serum iron (≤ 40 mcg/dL) had a higher rate of adverse
events, in-hospital and after 1 year. Lower and higher levels of ferritin
(1st and 3rd tertiles, ≤ 110; >219
ng/ml, respectively) were associated with a higher incidence of HF during
hospitalization and death at 1 year. A ferritin value >316 ng /mL was an
independent risk factor for death at 1 year (adjusted OR: 14; 95%CI: 2.6 to
75.9).ConclusionIn this population, iron metabolism alterations were associated with a higher
rate of adverse events and higher ferritin levels constituted an independent
mortality predictor in the long-term.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.